Compare AGIG & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | AGIG | GRML |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 2 | 5 |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.4M | 51.5M |
| IPO Year | N/A | 2022 |
| Metric | AGIG | GRML |
|---|---|---|
| Price | $0.91 | $0.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 157.7K | ★ 3.5M |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.97 | $0.25 |
| 52 Week High | $5.31 | $0.55 |
| Indicator | AGIG | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 28.73 | 26.05 |
| Support Level | N/A | N/A |
| Resistance Level | $1.26 | $0.44 |
| Average True Range (ATR) | 0.08 | 0.03 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 11.68 | 4.01 |
Abundia Global Impact Group Inc. is a technology solutions company operating in recycling, renewable energy, environmental change, fuels, and chemicals sectors, mainly focused on low-carbon energy solutions. The company uses waste plastics and biomass to produce crude or drop-in alternatives to fossil-derived energy, fuels, and chemicals through proprietary, licensed, and commercialized technologies, forming a complete process. It operates through its subsidiary and integrates feedstocks, technology, and off-take partners into a complete commercial chain. Its segments include Oil and Gas (O&G), which generates maximum revenue, and Renewables, which consists of its low-carbon fuels and renewable chemicals business.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.